Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26818530 | 0.80 | HPGDS (0.48) | WNT3APIK3CAABL1 | |
| SCHEMBL20743619 | 0.80 | LOXL2 (0.43) | WNT3AS1PR1CYP11B2LOXL2ABL1 | |
| SCHEMBL10021910 | 0.77 | NPC1 (0.35) | — | |
| SCHEMBL13728802 | 0.77 | PSEN1 (0.34) | WNT3AS1PR1ABL1S1PR3 | |
| SCHEMBL16352387 | 0.76 | MAPT (0.55) | PIK3CA | |
| SCHEMBL12786339 | 0.75 | NPC1 (0.44) | — | |
| SCHEMBL26818388 | 0.74 | WNT3A (0.39) | WNT3AS1PR1 | |
| SCHEMBL27545288 | 0.73 | NPC1 (0.38) | WNT3AS1PR1CYP11B2LOXL2ABL1 | |
| SCHEMBL15261780 | 0.72 | WNT3A (0.38) | WNT3AS1PR1CYP11B2ABL1S1PR3 | |
| SCHEMBL20873067 | 0.71 | CYP2A6 (0.56) | WNT3AS1PR1LOXL2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | WNT3A 1974/4885PIK3CA 3044/4885S1PR1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.